|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
A Historical Perspective on Radioligand Therapy and Novel Treatment Modalities in the Management of mCRPC
|
Neil H. Bander, MD
Neil Bander joins Charles Ryan providing a historical perspective on radioligand therapy and the history of prostate-specific membrane antigen (PSMA) for prostate cancer treatment. |
|
|
|
|
|
|
|
|
|
|
|
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer
|
Philip Kantoff, MD
Phil Kantoff, CEO of Convergent Therapeutics, sits down with Alicia Morgans to discuss the future of radioligand therapy in the treatment of advanced prostate cancer. |
|
|
|
|
|
|
|
|
|
|
| Combination Treatment Strategies with Radium-223 for mCRPC |
Michael Morris, MD
Michael Morris joins Alicia Morgans in a discussion on combination therapies with Radium-223 for treating metastatic castration-resistant prostate cancer (mCRPC). |
|
|
|
|
|
|
|
|
|
|
| Targeted Alpha Therapy for Prostate Cancer, the Next Generation of Alpha-Emitting Radiopharmaceuticals
|
| Evan Yu, MD
|
| When reviewing the current portfolio of targeted alpha therapy clinical trials available on the U.S. National Library of Medicine clinicaltrials.gov website, actinium is the most comprehensively explored alpha-emitter. Although PSMA is the most common target, other targets such as human kallikrein 2 and even neurotensin receptor 1 (NTSR1) are being evaluated.
|
|
|
|
|
|
| The Current Landscape of Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy
|
| Rashid Sayyid, MD MSc, Zachary Klaassen, MD MSc & Christopher J.D. Wallis, MD Ph.D.
|
| Radiopharmaceuticals are pharmaceutical agents which contain radioisotopes that emit radiation, which may be used for diagnostic or treatment purposes. Historically, beta-particle emitting agents including strontium-89 (Metastron), samarium-153 (Quadramet), phosphorus-32, and rhenium-186 were used as palliative therapies for patients with symptomatic bone disease. In this context, they are quite effective in relieving bone pain but did not significantly improve survival.
|
|
|
|
|
|
Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-Risk Prostate Cancer Prior to Radical Prostatectomy: A Single Arm Phase I Trial - Beyond the Abstract
|
| Michael Frumer, MD
|
| High-risk localized prostate cancer (HRPCa) is associated with a substantial risk for disease progression despite local treatment. Neoadjuvant systemic therapy has the potential to improve oncological outcomes by targeting the primary tumor and micro-metastatic disease. |
|
|
|
|
|
|
|
|
|
|
| Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2, for Advanced Prostate Cancer |
| Michael J. Morris MD
|
| Michael Morris presents the rationale and design of a phase 1 study examining JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2 in advanced prostate cancer. The primary endpoint of this study is safety, as measured by the incidence and severity [grading per NCI‑CTCAE V5.0] of AEs including DLTs, and to determine the RP2D. |
|
|
|
|
|
| Phase I/II Trial of Pembrolizumab and AR Signaling Inhibitor +/- 225Ac-J591 for Chemo-Naive Metastatic Castration-Resistant Prostate Cancer
|
| Scott Tagawa, MD
|
| The most clinically developed PSMA-targeting radiopharmaceutical is 177Lu-PSMA-617, a beta-emitting isotope that targets cells expressing PSMA, including prostate cancer cells. This agent has recently been shown to improve patient outcomes in two randomized clinical trials published recently.
|
|
|
|
|
|
| 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
|
| Madhav P. Yadav, MD
|
| Madhav Yadav presents an assessment of the safety and therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients with mCRPC. 225Ac-PSMA-671 TAT showed promising anti-tumor activity, sustained response, improved overall survival, and low treatment-related toxicities.
|
|
|
|
|
|
| Best Use of Lutetium-PSMA and Where To Put It in Sequencing Therapies Including Treatment Monitoring |
| Charles J. Ryan, MD
|
| Charles Ryan discusses the best use of Lutetium-PSMA and where to place it when sequencing therapies, including treatment monitoring. There is a clear benefit of 177Lu-PSMA-617 targeted radioligand therapy in the post taxane population of patients. |
|
|
|
|
|
|
